ea0065oc4.2 | Thyroid | SFEBES2019
Jeeyavudeen MohammadSadiq
, Johnson Elinor
, Graveling Alex
, McKiddie Fergus
, Duguid Rebecca
, Cluny Laura
, Bassett-Smith Victoria
, Gibb Fraser
, Strachan Mark
, Abraham Prakash
Background: High risk patients with differentiated thyroid cancer (DTC) undergoing radioiodine (I-131) treatment can be prepared by thyroid hormone withdrawal (THW) or with parenteral recombinant TSH (rhTSH). We compared two centres predominantly using THW or rhTSH to study the impact on radioiodine retention and length of hospital stay (LoHS).Methods: We retrospectively compared radioactivity at discharge following high dose I-131 therapy (35 GBq ...